Live Markets »News & Advice»Market News»Market News Details
Market News Details

Dr Reddy's launches Plaquenil's generic version in US after USFDA clearance

Press Trust of India/New Delhi 11 Jul 18 | 01:05 PM

Representative Image

Dr Reddy's Laboratories on Wednesday announced the launch of generic version of Plaquenil, used to treat malaria, lupus erythematosus, and rheumatoid arthritis, in the US.

Related Stories

    No Related Stories Found
Widgets Magazine

The launch follows approval of Hydroxychloroquine Sulfate tablets, a therapeutic equivalent generic version of Plaquenil, by the US Food and Drug Administration (USFDA), Dr Reddy's Laboratories said in a BSE filing.

Quoting IMS Health data, Dr Reddy's Laboratories, the Plaquenil brand and generic had US sales of approximately $215 million for the most recent twelve months ending in May 2018.

Dr Reddy's said its product Hydroxychloroquine Sulfate tablets are available in 200 mg tablets in the bottle count sizes of 100 and 500.

ALSO READ: Dr Reddy's Laboratories gets USFDA's approval for opioid addiction drug

Plaquenil is a trademark of Concordia International Corp.

Shares of Dr Reddy's Laboratories were trading at Rs 2,293.95 apiece, down 1.11 per cent from the previous close on the BSE.

Widgets Magazine


Company Price Gain (%)
Sun Pharma.Inds.559.902.72
Reliance Inds.1,128.552.23
ICICI Bank266.001.84
Axis Bank534.451.36


Currently No Poll Available.

Online Portfolio

You can create Online Portfolio here using the below button.

Widgets Magazine